Drug Sponsors

Bayer to restructure

Wednesday, May 27, 2015

The Bayer Group has released a financial update for 2014. The company had strengthened its life science businesses HealthCare and CropScience through acquisitions and decided to demerge the MaterialScience business. Dr. Marijn Dekkers, management board chairman, also listed four strategic priorities for Bayer’s successful further development.

[Read More]

Mylan clarifies Perrigo offer

Wednesday, May 27, 2015

Mylan was asked by the Irish Takeover Panel to issue the following clarification and retraction in accordance with the Irish Takeover Rules, relating to its firm intention to make an offer to acquire Perrigo. The clarification and retraction relates to certain forward-looking statements made by Mylan specifically during the pendency of the offer period concerning its long-stated target since 2012 of at least $6 in adjusted diluted earnings per share (EPS) by 2018, including recently in Mylan’s first quarter earnings press release of May 5.

[Read More]

Fosun Pharma, HOPU Investments, CEL Healthcare Fund, WuXi PharmaTech to acquire Ambrx

Friday, May 22, 2015

A consortium—consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU InvestmentsChina Everbright’s Healthcare Fund and WuXi PharmaTech—has signed a merger agreement to acquire Ambrx. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions.

[Read More]